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INTRODUCTION 63
6 Cross-referencing our gain-of-function screen of the kinome with previously published 116 loss-of-function screens, we identify AAK1 as a negative regulator of WNT-induced -catenin 117 transcription. Gain-and loss-of-function studies reveal that AAK1 negatively regulates WNT 118 signaling by promoting CME of LRP6. We also report and employ a novel potent and selective 119 cell active dual AAK1/BMP2K inhibitor, which potentiates WNT signaling. Full characterization 120 of this small molecule supports that it is the best available tool to interrogate AAK1 biology. 121
Unexpectedly, we discovered that WNT induces phosphorylation of AP2M1 by AAK1 in a 122 temporally delayed fashion at 8-10 hours post-WNT3A treatment. Therefore, we propose a 123 modified model whereby WNT-driven CME promotes a negative feedback mechanism to limit 124 pathway longevity. More broadly, this work contributes to the ongoing discussion of endocytosis 125 within WNT signaling by solidifying a role for the AAK1 kinase in removing LRP6 from the cell 126 plasma membrane. 127 128 RESULTS 129 7 HEK293T cells carrying the -catenin-activated Firefly luciferase reporter (BAR) and a 139 constitutively expressed Renilla (Ren) luciferase. Eighteen hours after kinase transfection, cells 140 were treated with WNT3A conditioned media (CM) for an additional 16 hours before lysis and 141 BAR/Ren reporter quantitation ( Supplementary Table 1 ). ANKRD6/Diversin and CTNNB1/-142 catenin served as negative and positive controls, respectively. Five kinases (AAK1, ADCK1, 143 ADCK2, MAST1 and TGFBR3) were validated by low throughput reporter assays in HEK293T-144 BAR/Ren cells (Fig. 1a) . Comparative analysis of this kinome gain-of-function screen in 145 HEK293T cells with two previously published siRNA-based loss-of-function screens in HT1080 146 sarcoma cells and A375 melanoma cells revealed a single common protein: AP2 Associated 147 Kinase 1 (AAK1) ( Supplementary Table 1 ) 25, 27 . Because of the well-established functional 148 connections between AAK1 and CME, and the emerging data on CME in governing WNT 149 pathway dynamics, we sought to understand how AAK1 negatively regulates the WNT pathway. 150
To validate and extend the discovery of AAK1 as a WNT inhibitor, we tested: 1) whether 151 siRNA-mediated silencing of AAK1 activated -catenin-driven transcription, 2) the cell-type 152 specificity of the AAK1-WNT phenotype, 3) whether AAK1 regulated the expression of 153 endogenous -catenin target genes, and 4) whether AAK1 affected the activity of non-WNT 154 signaling pathways. First, in agreement with AAK1 over-expression blocking WNT signaling 155 ( Fig. 1a) , siRNA silencing of AAK1 using two non-overlapping siRNAs increased BAR 156 expression in HT1080 fibrosarcoma cells and RKO colon cancer cells (Fig. 1b,c) . To visualize 157 reporter expression in real time, we silenced AAK1 in HT1080 cells carrying a BAR-mCherry 158 reporter. Quantitation of mCherry fluorescence confirmed that AAK1 knockdown activated the 159 BAR reporter (Fig. 1d) , while AAK1 over-expression suppressed BAR activity (Fig. 1e) . Third, 160 to rule out potential reporter-based artifacts, we quantified the expression of two WNT target genes 8 after AAK1 perturbation. AAK1 knockdown increased RNA expression of AXIN2 and NKD1 in 162 both HEK293T and HT1080 cells ( Fig. 1f,g) . Conversely, AAK1 over-expression led to decreased 163 RNA expression of AXIN2 and NKD1 in HEK293T cells ( Fig. 1h) . Fourth, because of its 164 established roles in CME, AAK1 might broadly regulate other signaling cascades. AAK1 over-165 expression did not affect TNF-driven NFκB reporter activity or TGF-driven SMAD reporter 166 activity ( Fig. 1i) . Together, these data establish that AAK1 negatively regulates WNT signaling 167 in cells derived from multiple tissue types. Importantly and consistent with its established role in 168 CME, AAK1 did not impact -catenin transcriptional activity in the absence of exogenous 169 WNT3A stimulation. 170 171
Discovery of a potent and selective inhibitor of AAK1 172
Indazole compound SB-742864 was previously identified as a semi-selective inhibitor of 173 AAK1 (in vitro IC50 = 220 nM) 28 . Optimization of SB-742864 via iterative medicinal chemistry 174 optimization led to compound 25A ( Fig. 2a) , a potent and selective inhibitor of AAK1 and the 175 closely related kinase, BMP2K. Further optimization to improve the selectivity led to SGC-AAK-176 1 ( Fig. 2a) , a chemical probe for AAK1 and BMP2K. A closely related molecule, SGC-AAK1-177 1N (referred to as 34A), which is devoid of activity on AAK1 or BMP2K, was identified for use 178 as a negative control compound. Full details of the chemistry program and analysis of the structure-179 activity relationships will be published elsewhere. Compounds 25A and SGC-AAK-1, but not 180 34A, both selectively inhibited AAK1 and BMP2K over the other members of the subfamily, 181
Numb-associated kinases GAK and STK16, in a TR-FRET binding displacement assay ( Fig. 2b , 182 
DMSO

Figure 2 -SGC-AAK1-1 is a potent and specific inhibitor of AAK1 and BMP2K that is active in cells. (a)
Chemical structures of the AAK1/BMP2K chemical probe SGC-AAK-1, the related AAK1/BMP2K inhibitor 25A, and the negative control compound 34A that has a similar chemical structure but does not inhibit AAK1 or BMP2K. (b) SGC-AAK-1 selectively bound AAK1 and BMP2K with a more than 30-fold difference in Ki in a TR-FRET binding displacement assay over the related kinases GAK and STK16. 16-point dose-response curves were measured in duplicate. (c) SGC-AAK1-1 has good selectivity over the human kinome. SGC-AAK1-1 was used at 1 µM concentration. Kinases for which SGC-AAK1-1 has a KD < 100 nM are marked with a large red circle and 100 nM < KD < 1.0 µM with a smaller red circle. (d) Isothermal titration calorimetry confirmed a dissociation constant (KD) of 120 nM for binding of SGC-AAK1-1 to AAK1. (e) A co-crystal structure of BMP2K (2.41 Å) bound to 25A revealed the binding mode of the inhibitor in the ATP site. (f,g) NanoBRET cellular target engagement assays in HEK293T cells showed that 25A (f) and SGC-AAK1-1 (g) both entered cells and directly bound to AAK1 and displaced a fluorescent tracer molecule from the ATP site. Cells were treated with serially diluted inhibitors in the presence of four different concentrations of a NanoBRET tracer molecule, and IC 50 values were calculated from a linear interpolation of the IC 50 values at each tracer concentration to obtain the predicted IC 50 in the absence of tracer. Measurements were made with three technical replicates. (h) Binding of SGC-AAK1-1 to BMP2K in cells was weaker than to AAK1 with IC 50 > 1 µM. (i) SGC-AAK1-1 inhibited the phosphorylation of the AP2M1 subunit at Thr156 in HEK293T cells in a concentration-dependent manner. HEK293T cells were treated with inhibitors for 2 hours before Western blot analysis. selectivity over a panel of 406 wild-type protein kinases at 1 µM concentration ( Fig. 2c,  185 Supplementary Fig. 1b , Supplementary Table 2 ) with only a small number of other kinases 186 inhibited with KD values within 30x of those of AAK1. Isothermal titration calorimetry measured 187 KD values for SGC-AAK1-1 of 120 nM and 490 nM against AAK1 and BMP2K respectively and 188 showed that binding had favorable enthalpy and unfavorable entropy ( Fig. 2d, Supplementary  189   Fig. 1c, Supplementary Table 3 ). Attempts to co-crystallise either inhibitor with AAK1 were 190 unsuccessful, but it was possible to obtain a co-crystal structure of 25A with BMP2K to 2.41 Å 191 resolution ( Fig. 2e, Supplementary Fig. 1d ,e,f, Supplementary Table 4 with IC50 values of around 240 nM, and more weakly to BMP2K, with IC50 values of 600 nM and 202 1.5 µM respectively ( Fig. 2f,g,h, Supplementary Fig. 1g ). To demonstrate that binding to AAK1 203 inhibited its enzymatic activity in cells, phospho-AP2M1 (Thr156) levels were observed by 204
Western blotting after 2 hour treatment of HEK293T cells with serially diluted SGC-AAK1-1, 205 resulting in a dose-dependent decrease of pAP2M1 starting below 1 µM in agreement with the 206 NanoBRET data (Fig. 2i) . 207 10 To confirm and extend these data, we next tested SGC-AAK1-1 and 25A in a series of 208 experiments to evaluate its potency of AAK1 inhibition in cells and regulation of WNT signaling. 209
First, we treated HT1080 cells with SGC-AAK1-1 and evaluated AAK1-dependent 210 phosphorylation of AP2M1. SGC-AAK1-1, along with 25A, both significantly reduced 211 phosphorylation of AP2M1 (T156), compared to controls, DMSO and 34A (Fig. 2j) . Second, 212 treatment with SGC-AAK1-1 or 25A activated WNT-driven BAR activity compared to controls 213 (DMSO and 34A) in a dose-dependent manner (Fig. 2k) . Importantly, 25A also significantly 214 upregulated WNT target genes AXIN2 and NKD1 in HT1080 cells, as compared to DMSO control 215 and 34A ( Fig. 2l) . Together, these results indicate that 25A and SGC-AAK1-1 block AAK1 kinase 216 activity, resulting in increased WNT/-catenin signaling. 217
218
AAK1 promotes CME of LRP6 to inhibit WNT signaling 219
Several recent studies report that CME negatively regulates WNT signaling by reducing 220 the presence of the receptor complex on the plasma membrane 18,20,22 . Given the well-established 221 role of AAK1 in phosphorylating AP2M1 to facilitate CME 10,12-14 , our discovery of AAK1 as a 222 negative regulator of WNT signaling is not entirely unexpected. That said, AAK1 has not 223 previously been shown to regulate WNT signaling, and certainly, the molecular mechanisms 224 governing CME within the WNT pathway and its homeostasis are not well-defined, with several 225 remaining questions and conflicting studies 16-18,20,22-24 . To confirm that AAK1 functions within 226 membrane proximal steps of WNT signaling, we stabilized -catenin protein levels with a GSK3 227 inhibitor (CHIR99021) following either AAK1 over-expression or siRNA silencing. CHIR99021-228 mediated activation of the BAR reporter was not affected by AAK1 depletion or over-expression 229 (Fig. 3a) . As expected, -catenin knockdown blocked BAR activation by AAK1 silencing ( Supplementary Fig. 2a) . These results indicate that AAK1 functions upstream of -catenin and 231 the destruction complex. Next, the role of endocytosis in AAK1-mediated repression of WNT 232 signaling was evaluated using two AAK1 mutants: 1) AAK1-74A, which lacks kinase activity, 233
and 2) AAK1-AID, which encodes a truncated form of AAK1 that cannot bind the AP2 complex 12 . 234
Neither AAK1-74A nor AAK1-AID significantly repressed the BAR reporter (Fig. 3b) , suggesting 235 that both interaction and kinase activity are required for AAK1-mediated repression of WNT 236 signaling. A role for clathrin and CME in AAK1-driven WNT suppression was tested by siRNA 237 silencing of clathrin and by pharmacological inhibition clathrin-coated vesicles. Two non-238 overlapping clathrin siRNAs effectively silenced clathrin expression, and blocked AAK1-239 dependent suppression of the BAR reporter in HT1080 cells (Fig. 3c) . Similarly, treatment with 240 chlorpromazine, an established albeit promiscuous CME inhibitor 17,30,31 , suppressed WNT 241 signaling induced by AAK1 silencing (Fig. 4D) . These experiments suggest that AAK1 represses 242 WNT signaling in a clathrin-and kinase-dependent manner. 243
We next examined the effect of AAK1 on LRP6 protein levels using cell surface 244 biotinylation assays and flow cytometry. AAK1 over-expression decreased LRP6 protein levels at 245 the plasma membrane ( Fig. 4a) . Additionally, AAK1 knockdown by siRNA increased LRP6 246 surface expression levels (Fig. 4b) . Based on the observation that total LRP6 levels seem to 247 decrease with AAK1 knockdown (Fig. 4b) , we quantified total LRP6 expression across 6 248 biological replicates and demonstrate that with AAK1 knockdown, total LRP6 levels increase (Fig.  249   4c) . To validate the changes in surface LRP6 expression findings in an orthogonal platform, we 250 used flow cytometry to quantify cell surface LRP6 levels in HEK293T cells. Here, AAK1 over-251 expression decreased LRP6 surface levels while AAK1 knockdown increased LRP6 surface levels 252 ( Fig. 4d,e ). Together, these data indicate that AAK1 negatively regulates LRP6 abundance on the 253 plasma membrane. As such, we hypothesized that AAK1 and LRP6 co-complex. Using HEK293T 254 cells, immunoprecipitation and Western blot analysis of HA-LRP6 protein complexes revealed the 255 presence of over-expressed FLAG-AAK1 (Fig. 4f) . Similarly, immunoprecipitation of HA-LRP6 256 co-purified endogenous AAK1 and reciprocally, immunopurification of over-expressed FLAG-257 AAK1 revealed co-complexed endogenous LRP6 (Fig. 4g,h, respectively) . Finally, 258 immunoprecipitation of endogenous AAK1 showed co-complexed endogenously expressed LRP6 259 ( Fig. 4i) . Interestingly, WNT3A stimulation suppressed the association of LRP6 and AAK1 in all 260 experiments ( Fig. 4f-i) . 261 AAK1 silencing potentiated WNT3A-driven -catenin activation and increased LRP6 262 protein levels in whole cell lysate and on the membrane (Fig. 4b,c,e ). Because cargo targeted by 263 clathrin-mediated endocytosis can be directed to lysosomes for degradation, we tested if the 264 decreased LRP6 levels we observed following AAK1 over-expression was due to CME of LRP6 265 and subsequent lysosomal degradation. AAK1 was over-expressed in HEK293T cells before 266 treatment with bafilomycin A1, an inhibitor of lysosomal acidification. Western blot analysis 267 established that bafilomycin A1 treatment rescued AAK1-driven downregulation of LRP6 ( Fig.  268   4j) . Together, these results suggest that AAK1 inhibits WNT signaling by inducing CME 269 endocytosis and lysosomal degradation of LRP6. software. (d,e ) LRP6 surface staining as detected by flow cytometry analysis in HEK293T cells transfected with an AAK1 over-expression construct for 24 hours (d) or an AAK1 siRNA construct for 72 hours (e). All experiments were quantified using FlowJo software. Experiment was performed in 4 biological replicates. (f) HEK293T cells were co-transfected with FLAG-AAK1 or control FLAG-hcRED and HA-LRP6 over-expression constructs. Twenty-four hours post-transfection, cells were treated with WNT3A CM for 1 hour. Western blot analysis of immunoprecipitated HA-LRP6. (g) HEK293T cells were transfected with HA-LRP6 for 24 hours and then treated with WNT3A CM for 1 hour. HA-LRP6 was immunoprecipitated, and the Western blot was probed for endogenous AAK1. (h) HEK293T cells were transfected with the FLAG-AAK1 or FLAG-GFP over-expression construct for 24 hours and then treated with WNT3A for 1 hour. IP of FLAG-AAK1 was conducted to visualize endogenous LRP6 as detected by Western blot. (i) Endogenous AAK1 IP in HEK293T cells treated as WNT3A CM for indicated times (untreated, 1, 9 hours) then endogenous LRP6 levels were visualized via Western blot analysis. (j) HEK293T cells were transfected with FLAG-AAK1 or FLAG-GFP over-expression constructs. Twenty-four hours post-transfection, cells were treated for 6 hours with the autophagy inhibitor, Bafilomycin A1 (100 nm) or DMSO control prior to cell harvest, then analyzed by Western blot for endogenous LRP6 and AAK1 levels. The box and whisker plot represents LRP6 expression normalized to β-tubulin from four biological replicates quantified by LiCOR software. All panels: Data are representative of biological triplicates, unless otherwise stated. * p<0.05. For complete statistical analysis, see methods and materials section. 13 phosphorylation of AP2M1. Time course analysis in HT1080 cells revealed WNT3A induced 277 phosphorylation of AP2M1 at 8-10 hours post treatment, with no change in total AP2M1 or AAK1 278 protein levels (Fig. 5a) . To rule out artifacts due to the use of WNT3A conditioned media and to 279 extend relevance to a second cell type, we treated HT1080 cells (Supplementary Fig. 3a) and 280 HEK293T (Supplementary Fig. 3c ) cells with recombinant human WNT3A (rhWNT3A) over a 281 time course of 4 to 16 hours. Western blot analysis revealed an increase in pAP2M1 protein levels 282 8-10 hours post WNT3A stimulation. Further, a pulse of WNT3A (15 minutes) induced a similar 283 increase in AP2M1 phosphorylation as a prolonged WNT3A treatment ( Supplementary Fig. 3b,  284   d) . The WNT3A-induced phosphorylation of AP2M1 required AAK1 expression and activity. 285 First, HT1080 cells or HEK293T cells were treated with WNT3A CM and the AAK1 inhibitor, 286 25A, before Western blot analysis of phosphorylated AP2M1 -25A blocked WNT3A-induced 287 phosphorylation of AP2M1 ( Supplementary Fig. 3b,d) . Second, siRNA silencing of AAK1 288 similarly suppressed WNT3A-induced phosphorylation of AP2M1 (Fig. 5b) . These data support 289 a model where prolonged WNT3A treatment establishes an AAK1-driven negative feedback loop 290 wherein CME of LRP6 decreases its abundance on the plasma membrane. 291
Intrigued with the delayed WNT3A-induced phosphorylation of AP2M1 by AAK1, we 292 performed a series of functional assays to identify requisite signaling events. First, we found that 293 AAK1-mediated pAP2M1 accumulation was induced by rhWNT3A (3A) and rhWNT5A (5A), 294 the latter of which signals in a -catenin-independent fashion (Fig. 5c) . Second, inhibition of 295 GSK3 with CHIR99021 did not result in elevated pAP2M1 levels, suggesting that WNT3A-296 induced pAP2M1 did not require -catenin-dependent transcription (Fig. 5d) . In agreement with 297 these data, inhibiting WNT3A-dependent transcription with over-expressed dominant-negative 298 TCF7L2/TCF4 (dnTCF7L2/dnTCF4) did not affect pAP2M1 accumulation (Fig. 5e) . Third, a unt 6 8 10 9
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(T156) Western blot analysis of HT1080 cells transfected with either AAK1 or control siRNA for 72 hours. Cells were then treated with rhWNT3A (200 ng/mL) for 15 minutes, then the media was changed for fresh, complete DMEM and cells were incubated for 9 hours. (c) Western blot analysis of pAP2M1 levels in HEK293T cells treated with either rhWNT3A (3A) or rhWNT5A (5A) (200 ng/mL) for 9 hours. The box and whisker plot represents phosphorylated LRP6/total LRP6 expression from four biological replicates quantified by LiCOR software. (d) Western blot analysis of HT1080 cells treated with either CHIR990201 compound (1 µM) or rhWNT3A (200 ng/mL) for the indicated time. (e) HEK-293T cells were transfected with FLAG-dnTCF4 for 24 hours. Cells were then treated with WNT3A for 15 minutes, then the media was changed for fresh, complete DMEM, incubated for 9 hours, and analyzed by western blot. (f) Western blot analysis of HT1080 cells treated with WNT3A CM for 15 minutes, then the media was changed for complete DMEM containing either carbachol (100 µM) or neomycin (100 µM). Cells were incubated for 9 hours prior to cell harvest. (g) Western blot analysis of HT1080 cells transfected with siRNA against PI4K2α for 72 hours and pulsed with WNT3A CM for 15 minutes and then incubated for 9 hours. All experiments were performed in biological triplicate. previous studies established that PIP2 levels increase following short-term (4 hour) WNT3A 300 treatment, and that PIP2 is required for LRP6 signalosome formation 19,21 . Further, PIP2 was shown 301 to recruit AP2 to the signalosome, leading to clathrin-mediated endocytosis of LRP6 19 . Thus, we 302 hypothesized that PIP2 is required for WNT3A-induced phosphorylation of AP2M1 by AAK1. To 303 test this hypothesis, we inhibited PIP2 by treating cells with neomycin or carbachol, both of which 304 block PIP2 signaling 32,33 . Treatment of HT1080 cells with neomycin or carbachol blocked 305 WNT3A-induced phosphorylation of AP2M1 (Fig. 5f) . Furthermore, we blocked PIP2 production 306 by silencing the PI4K2 kinase with 2 non-overlapping siRNAs. PI4K2 phosphorylates 307 phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PI4P) and is required for 308 subsequent PIP2 production 34 . In agreement with the neomycin or carbachol experiments, PI4K2 309 silencing in HT1080 cells blocked WNT3A-dependent increase in pAP2M1 (Fig. 5g) . We 310 conclude that WNT ligands drive AAK1-dependent phosphorylation of AP2M1 in a manner that 311 is: 1) temporally-delayed from signalosome formation, 2) independent of -catenin-mediated 312 transcription and 3) dependent upon PIP2 production. 313
314
DISCUSSION 315
Clathrin-mediated endocytosis is a well-established regulator of WNT signaling, although 316 whether CME promotes or inhibits the WNT pathway remains debated 7,17,19-21,23,24 . Certainly, 317 contextual and temporal features in CME-directed WNT studies must be considered. As a central 318 and positive regulator of CME, our discovery of AAK1 as a WNT modulator is of no surprise. 319
Collectively our data show that AAK1 negatively regulates -catenin-dependent WNT signaling 320 through CME endocytosis of LRP6. Although the experiments have not yet been done, we 321 speculate that Frizzled is similarly targeted by AAK1 and CME. In the course of our studies, we 322 We hypothesize that PIP2 levels continue to accumulate with longer WNT exposure. Phosphorylation of AP2M1 by AAK1 promotes binding to cargo sorting signals on LRP6, and enhances the growth and stabilization of clathrin-coated pits. (e) PIP2 levels accumulate to a specific threshold, driving AAK1 dependent AP2M1 phosphorylation. This results in growth of the clathrin-coated pit and cargo capture of the LRP6 signalosome, which undergoes CME and is ultimately degraded.
discovered an unexpected WNT-induced phosphorylation event on T156 of AP2M1. This was 323 mediated by AAK1, and reproducibly occurred at 8-10 hours post WNT treatment. In Figure 8 , we 324 summarize our findings in a multi-step model that integrates WNT-driven signalosome formation, 325 PIP2 production, AAK1, AP2M1 phosphorylation and CME of LRP6. 326
In the absence of WNT ligand, Frizzled and LRP6 remain dissociated, allowing for -327 catenin phosphorylation, ubiquitylation and degradation (Fig. 6a) 3, 4 . Within minutes of WNT 328 stimulation, the LRP6 signalosome forms, resulting in transient repression of -catenin 329 phosphorylation by GSK3 (Fig. 6b) 7 . The newly formed LRP6 signalosome requires PIP2 for 330 assembly and contains both clathrin and AP2 (Fig. 6b) 21 . Based on our data, we suggest that long-331 term (8-10 hours) WNT stimulation induces a spike in AAK1-dependent phosphorylation of T156-332 AP2M1. This promotes clathrin polymerization, clathrin-coated pit stabilization and ultimately 333 CME of LRP6, thus constituting a WNT-driven and AAK1-dependent negative feedback loop. 334
Phosphoinositide is converted to PIP2 by PI4K2 and PIP5K 34 . Importantly, PIP5K1 335 association with the DIX domain of DVL1/2/3 results in activation of PIP5K1 21, 35 . We hypothesize 336 that through this mechanism, WNT-driven recruitment of DVL to the LRP/Frizzled receptor 337 complex results in a time-dependent increase in local PIP2 production. PIP2 and cargo proteins 338 allosterically activate the AP2 complex, thus driving clathrin polymerization and maturation of 339 clathrin-coated pits (Fig. 6c) 9, 11 . Phosphorylation of AP2M1 by AAK1 stabilizes the AP2 complex 340 in an open/active confirmation, promoting the binding of clathrin and cargo proteins and ultimately 341 enhancing CME (Fig. 6d) 13 . Although we do not yet understand the mechanistic details, we 342 speculate that PIP2 levels continue to rise hours after WNT stimulation, possibly triggering an 343 increase in AAK1-dependent phosphorylation of AP2M1 and CME of LRP6 (Fig. 6e) . Further 344 studies that quantify PIP2 levels at 8-10 hours post WNT stimulation are needed. Alternatively, 345 16 the AP2 complex has been reported to cycle between phosphorylated and dephosphorylated states 346 during CME and that this cycling is necessary for robust CME 11 . Therefore, it is possible that WNT 347 stimulation shifts the AAK1/phosphatase balance to favor phosphorylated AP2M1. The molecular 348 events suggested in this time-delayed model are consistent with the timing reported in the GSK3- The AP2 complex binds Yxxɸ or dileucine motifs within the intracellular domains of 360 transmembrane cargo proteins 36, 37 . Through phosphorylation of T156-AP2M1, AAK1 was 361 previously shown to promote association of the AP2 complex with cargo 10 . Interestingly, in co-362 immunoprecipitation experiments, we discovered an association between AAK1 and LRP6. AP2 363 interacts with LRP6 through a conserved Yxxɸ motif, which is required for LRP6 signalosome 364 formation 19,24 . Thus, it is prossible that the AAK1-LRP6 co-complex reported here requires AP2 365 as a bridge. We also report that the AAK1-LRP6 co-complex dissolves following treatment with 366 WNT3A. While further experimentation is needed to define the dynamics of protein-protein 367 interactions during CME of LRP6, it is possible that following AAK1-dependent phosphorylation 368 of AP2M1, AAK1 dissociates from the LRP6/AP2 complex. 369 AAK1 contributes to several neurological disorders, including neuropathic pain, 370
Alzheimer's Disease, Parkinson's Disease, schizophrenia and Amyotrophic Lateral Sclerosis 38, 39 . 371 AAK1 has a described role in dendrite branching and spine development 40 , and through the 372 regulation of Neuregulin1/ErbB4, AAK1 has been linked to schizophrenia 41 . Just recently, the 373 LX9211 AAK1 inhibitor entered phase 1 clinical trials for neuropathic pain. Here we report the 374 development of a potent and selective AAK1 pharmacological inhibitor (SGC-AAK1-1). SGC-375 AAK1-1 demonstrates improved biochemical selectivity over the phase 1 clinical agent LX9211 376 and is confirmed to be cell active. Thus, we report the best available chemical tool to study 377 AAK1/BMP2K pathways and related biology. Like the lead compound 25A, SGC-AAK1-1 378 inhibited AAK1-dependent phosphorylation of AP2M1 and activated WNT signaling. Looking 379 forward, in vitro and in vivo neural-directed studies of SGC-AAK1-1 and its comparison with 380 LX9211 are needed. Further, while we describe a role for AAK1 in negatively regulating WNT 381 signaling, AAK1 also inhibits Neuregulin1/ErbB4 and positively regulates the NOTCH 382 pathway 41,42 . Therefore, AAK1 inhibitors may also regulate these signaling cascades and 383 consequently prove therapeutically beneficial in diseases with misregulated NOTCH or 384 Neuregulin1/ErbB4 signaling. 385 386 387
MATERIALS AND METHODS 388
Cell lines and tissue culture: All cells were cultured at 37 C and 5% CO2. HT1080, HEK293T, 389 RKO, Lcells, and WNT3A expressing Lcells were obtained from American Type Culture 390 18 Collection (ATCC) (Manassas, VA) and grown in DMEM with 10% FBS. Each cell line was 391 routinely tested for contamination and passaged no more than 20 passages from the original ATCC 392 stock. Cells were treated at the indicated concentrations with the following compounds: 393 CHIR99021 (Cayman Chemicals), chlorpromazine HCL (Sigma-Aldrich), bafilomycin A1 394 (Cayman Chemicals), rhWNT3A (PeproTech), rhWNT5A (R&D), neomycin trisulfate salt 395 hydrate (Sigma-Aldrich) and carbachol (EMD Chemicals). 396 397 WNT3A conditioned media: Conditioned media was collected as described by ATCC. Briefly, 398 WNT3A and control Lcells were grown to 100% confluency before fresh media was added, 399 conditioned for 48 hours, then collected. 400
401
DNA constructs and siRNAs:
The human kinase open reading frame library was obtained from 402
Addgene (cat# 1000000014) and cloned into a custom pHAGE-CMV-FLAG vector using 403
Gateway cloning technology. All constructs were N-terminally sequence verified. Wild type 404 AAK1 and mutants were a gift from Dr. Sean Conner (University of Minnesota). GFP-LRP6, HA-405 LRP6, ANKRD6, and FLAG-dnTCF7L2 were kindly provided by Dr. Randell Moon (University 406 of Washington). ADCK1, ADCK2, MAST1, and TGFBR3 were obtained as part of the kinome 407 library from Addgene. All siRNAs were obtained from Life Technologies (ThermoFisher, 408
Waltham, MA), and sequences are provided in Supplementary Table 5 . 409 410 Transcriptional reporter assays: All luciferase reporter assays and IncuCyte fluorescent reporter 411 assays were performed as previously described 26 . Firefly luciferase and the Renilla (Ren) control 412 were detected using the Promega Dual-Luciferase Reporter Assay System per the manufacturer's 413
